Form 4: Abbott Laboratories Vice President John A. McCoy, Jr. Reports Stock Transactions

John A. McCoy, Jr., a Vice President at Abbott Laboratories, reported the disposition of company stock to cover tax obligations and a sale of shares.

Summary

• On September 1, 2024, John A. McCoy, Jr., a Vice President of Abbott Laboratories, had 18,708 common shares.
• On September 1, 2024, 52 common shares were disposed of at $113.27 to cover tax obligations.
• On September 4, 2024, 27 common shares were sold at $114.83.
• Following these transactions, McCoy directly owns 18,681 common shares.
• McCoy also indirectly owns 56 shares through a Profit Sharing Trust as of September 1, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by a company insider, which is a routine regulatory filing.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of company executives and potentially gain insights into their perspectives on the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The transactions reported are relatively small in scale, suggesting they are unlikely to have a significant impact on the overall market capitalization of Abbott Laboratories.
• Comparable companies in the pharmaceutical and healthcare sector also have similar insider trading reporting requirements.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders due to their small scale.

Key Dates